ClinicalTrials.gg
RecruitingNCT07574151ACCESS-TADUpdated Jun 30, 2026

Accessing the Clarity and Acceptability of Recruitment Materials for a Study on Thoracic Aortic Disease Surveillance

An observational study in Thoracic Aortic Disease, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by University of Nottingham · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Aortic Diseases with a site in United Kingdom — 4 open to participants now, 6 under way, none of them phase 3. Aortic Diseases · United Kingdom.

Started
2026
the only one that year
Observational
8 of 13
3 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
University of Nottingham

Among the 13 studies in Aortic Diseases with a site in United Kingdom, this one is the only one that started in 2026, is one of 8 observational ones, and was the 13th registered.

Aortic Diseases

109 studies on the registry are indexed under Aortic Diseases; 44 are open to participants now.

Browse Aortic Diseases studies →

Open to participants now

4 of the 13 studies in Aortic Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 36 Aortic Diseases studies recruiting now, 28 (78%) set no upper age limit and 2 (6%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Aortic Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

People who are invited to take part in health research are usually given written information, such as invitation letters, and information sheets. These documents are essential because they help people understand what the study involves and decide whether they want to take part. However, many studies have shown that research information is often too complex, too long, or written in technical language. This can make it difficult for people to fully understand the study and give informed consent.

This study aims to assess how clear, accessible, and acceptable draft research documents are for a proposed future doctoral study related to thoracic aortic disease. Thoracic aortic disease is a long-term condition that requires regular monitoring, and people in surveillance programmes may be invited to take part in research. It is therefore important that study information is clear, sensitive, and easy to understand.

In this study, staff and students from the University's School of Health Sciences will be asked to review draft recruitment materials. These materials include a study invitation, an information sheet, and interview guide. Participants will be asked to give feedback on how easy the documents are to read, whether the information is clear, whether the tone feels appropriate, and whether the amount of information feels reasonable.

The study will also use a standard readability tool to assess whether the documents are written at a level suitable for the public.

This research does not involve patients and is considered low risk. Its purpose is to improve research materials before they are used with patients, helping to support informed consent, reduce confusion, and improve ethical and inclusive research practice in future studies.

Read the detailed description

BACKGROUND AND RATIONALE:

Recruitment materials such as information sheets, consent forms, and questionnaires help people decide whether they want to take part in research. These documents are important because they explain what the study involves and help people make an informed choice. If the information is too technical, too long, or given at the wrong time, people may feel confused, anxious, or decide not to take part.

People with thoracic aortic disease (TAD) attend regular hospital appointments for monitoring and imaging. During these visits, they may be invited to take part in research studies. These moments can be stressful, and patients may find it difficult to process complex research information.

This study will explore how recruitment materials are written, when they are given to patients, and how patients understand them in the context of thoracic aortic disease surveillance. The aim is to identify ways to make research information clearer, more appropriate, and easier to understand, so that people can make informed decisions about participation.

The findings will be used to improve recruitment materials and strategies for a future doctoral research study. This will help support ethical recruitment, reduce participant burden, and promote fair and inclusive participation in thoracic aortic disease research.

The study seeks to answer the following research questions:

  • Are the recruitment research materials (including the study invitation, participant information sheet, and interview topic guide) clear and understandable?
  • Are the materials written at an appropriate reading level for the public?
  • How do potential participants perceive the tone, emotional impact, and acceptability of the materials?
  • Do the materials clearly explain what participation would involve, including time commitment and expectations?
  • What improvements can be made to enhance clarity, accessibility, and acceptability prior to use in future research?

STUDY AIMS

Main Aim To assess the clarity, accessibility, and acceptability of proposed Recruitment research materials developed for future doctoral study.

Objectives

  • To evaluate whether Recruitment materials are clear and understandable.
  • To assess the readability of materials using recognised readability tools.
  • To explore perceptions of emotional tone and information burden.
  • To examine the acceptability of proposed research procedures and participant burden
  • To refine materials in preparation for further doctoral research.

STUDY DESIGN

Methodology:

This study uses a qualitative feasibility design to explore whether and how recruitment materials could be improved before using in a future doctoral research project. Qualitative methods are appropriate to examine perceptions of clarity, tone, accessibility, and perceived burden, which cannot be fully captured using quantitative measures. The study aims to generate practical insights rather than statistically generalisable findings, consistent with feasibility research principles.

Sampling Strategy:

Departmental mailing lists and internal communication will be used in a convenience sampling strategy. Recruitment materials will be widely distributed throughout the School of Health Sciences, and participation will be completely voluntary to reduce selection bias.

Methods of Data Collection:

Written feedback will be collected via an electronic form containing free text response questions. If responses lack sufficient depth, a small number of follow-up interviews or one focus group may be conducted to clarify key issues, minimising participant burden.

The form will be hosted on Microsoft Forms within the University of Nottingham secure Microsoft 365 platform, with access restricted to the research team. If written responses lack sufficient depth, a small purposive sample (2-6 participants) may be invited to follow-up interviews or one focus group.

Study Sequence and Duration:

The data collection tool is designed to balance depth of feedback with minimising participant burden; the estimated completion time is 15-20 minutes. If written responses do not provide sufficient depth to inform revisions, a small subset of participants will be invited to take part in follow up semi structured interviews (approximately 2-6 interviews) or one focus group will be convened to explore specific issues in more detail.

Number of participants \& group allocations:

The research aims to recruit approximately 20-30 adults aged 18 or over who can read and understand English in accordance with feasibility research standards. This sample size is adequate for identifying recurring issues relating to clarity, accessibility, and acceptance while keeping data volume manageable for thematic analysis.

Methods of Data Analysis:

Qualitative data will be analysed using Braun and Clarke's (2006) reflexive thematic analysis. An inductive approach will allow unanticipated themes to emerge, appropriate for the study's exploratory aims. Analysis will involve familiarisation, initial coding (focusing on clarity, accessibility, tone, and burden), theme development, review, and refinement, followed by defining and naming final themes. Reflexive notes will document analytic decisions throughout. Readability scores will be integrated with qualitative interpretations by examining sections identified as challenging alongside participant feedback. This combined approach supports triangulation and enhances the credibility and depth of findings.

Recruitment Recruitment will take place through online advertisements, email circulation, and other low risk public facing channels. No direct approach or targeted recruitment of vulnerable groups will occur.

Information provided to participants:

A study invitation explaining the purpose of the research, what participation involves, that participation is voluntary, and the anticipated time commitment will be included in the recruitment materials.

The invitation will be sent out through departmental mailing lists and, if applicable, staff communication platforms or internal virtual learning environments. The recruitment message will make it clear that participation is completely voluntary.

A Participant Information Sheet (PIS) will be sent to prospective participants who indicate interest. The aims, ethical approvals, research activities involved in the study and the researcher's and supervisor's contact information will all be provided in this document. The feedback form will only be accessible to those who have given their informed consent. This recruitment strategy reduces the possibility of perceived pressure, especially in situations where staff-student power relations may present and is consistent with ethical guidelines for low-risk university-based research.

Informed Consent:

Informed consent will be obtained prior to any data collection and will be completed electronically.

Participants will be given adequate time to read the PIS before deciding whether to take part. Contact details for the researcher and supervisor will be provided so that participants can ask questions or request clarification before consenting.

Consent will be recorded using a single online consent form. This form will include consent for:

  • participation in the written feedback component, and
  • being contacted for an optional follow-up interview or focus group, should further clarification be required.

Participants must actively confirm each consent statement (e.g. by ticking mandatory boxes) before proceeding. Data collection will not be possible unless consent has been provided.

Participation in any follow-up interview or focus group remains voluntary. Participants will be required to confirm consent before being interviewed or before taking part in an interview or focus group (as applicable).

Participant confidentiality:

The study staff will safeguard the privacy of participants' personal data. The study will comply with the General Data Protection regulation (GDPR) Data Protection Act 2018, which requires all personal data to be anonymised as soon as it is practical to do so. The processing of the personal data will be minimised by making use of a unique study ID number only on all study documents and any electronic database(s). Documents (such as consent forms) that contain identifying data and/or information allowing this to be linked to the participant ID will be stored separately under strict access controls. All documents will be stored securely and only accessible by study staff and authorised personnel. If participants agree for their contact details to be kept for the purpose of inviting them to take part in future research studies, their name, contact details will be stored on a separate database under strict access controls.

Discontinuation/ withdrawal of participants from study:

Participants may withdraw from the study at any time without giving a reason and without consequence. They may choose to:

  • Withdraw from further involvement but allow data collected up to that point to be retained; or
  • Withdraw and request deletion of their identifiable data, provided this occurs before anonymisation.

Once data has been anonymised, it will no longer be possible to remove an individual's contribution. This includes transcripts of audio recordings and focus group data, where individual comments cannot be separated without compromising the dataset. These limits will be explained in the PIS.

Definition of end of study The end of participant involvement in the study is the date of submission of feedback and if needed the date of an interview or focus group session.

03

Conditions studied

  • Thoracic Aortic Disease

Browse trials for

Keywords

  • Surveillance
  • Recruitment materials
  • Clarity
  • Acceptability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults aged 18 or over who can read and understand English

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Able to read and understand English

Exclusion criteria

Exclusion Criteria:

  • Individuals under 18
  • Individuals unable to provide
  • Individuals unable to read or understand English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study population

    Adults aged 18 or over who can read and understand English.

    Other: Acceptability and Clarity

Interventions

  • OtherAcceptability and Clarity

    All study participants are assessing the clarity and acceptability of Recruitment Materials for a Study on Thoracic Aortic Disease Surveillance

06

What researchers measure

Primary outcomes

  1. Clarity of recruitment materials

    How well participants understand information provided

    Time frame: up to 24 weeks

07

Study locations

1 of 1 sites recruiting
  • School of Health Sciences ( University of Nottingham)
    Nottingham, United Kingdom
    Recruiting
    • Charles B Mensah, Mr · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jul 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 7, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Jul 31, 2026
CompletionEst.
Aug 12, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07574151
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Mar 11, 2026
Primary completion
Jul 31, 2026 (estimated)
Completion
Aug 12, 2026 (estimated)
Last update
Jun 30, 2026

Study contacts

Charles B Mensah, MA Research Methods- Health
Contact
ntxcm25@nottingham.ac.uk
+44
Charles B Mensah, MA Research Methods -Health
study director · University of Nottingham
Lesley Halliday, Dr
principal investigator · University of Nottingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion